Reading Time: 3 minutes
As Americans grow increasingly concerned about chronic illness, food safety, and rising healthcare costs, new leadership at the Food and Drug Administration is drawing praise from conservatives and health advocates alike. Under acting Commissioner Kyle Diamantas, the FDA is reportedly placing renewed emphasis on food safety, reducing harmful additives, streamlining drug approvals, and improving treatments for rare diseases.
Get prayer updates from IFA.
From Just the News:
The Food and Drug Administration is garnering praise for bringing a heightened focus to efficiency, rare diseases and food safety under new acting Commissioner Kyle Diamantas, who has already achieved success as the agency’s deputy commissioner for food.
“He made some great strides forward already in trying to get out some of the petroleum-based derivatives that are in food, the additives, bringing attention to ultra-processed foods,” Kansas GOP Sen. Roger Marshall, a physician, recently told Just The News.
As the FDA”s deputy commissioner for food, Diamantas, a former food and drug attorney, led the agency’s Human Foods Program with a focus on nutrition, safety, resource allocation and policy. He stepped into the top role mid-May after former Commissioner Dr. Marty Makary’s resignation.
The FDA’s new direction follows several reforms launched under former Commissioner Dr. Marty Makary, who earned praise from many conservatives for aggressively addressing synthetic food dyes, infant formula safety, AI-assisted regulatory tools, and rare disease treatments. Supporters say the agency is now moving toward a more practical and efficient model that prioritizes both public safety and medical innovation.
One major focus has been the growing concern over ultra-processed foods and chemical additives commonly found in the American food supply. Critics argue that the FDA’s longstanding “Generally Recognized as Safe” process has allowed food companies too much authority to determine whether ingredients are safe for consumers. Some additives currently permitted in the United States have already been banned or heavily restricted in Europe due to potential health risks.
Health experts interviewed in the report also raised concerns about corruption and revolving-door relationships between federal regulators and pharmaceutical companies. Former FDA senior medical analyst Dr. David Gortler warned that many agency leaders eventually leave government service for lucrative positions within Big Pharma, creating incentives that may not always align with the public interest.
Meanwhile, supporters of the FDA reforms say streamlining the drug approval process could help lower healthcare costs and accelerate treatment options for patients suffering from rare or life-threatening diseases. Senator Roger Marshall argued that while safety remains essential, doctors and patients should have greater freedom to weigh the risks and benefits of experimental treatments rather than relying solely on lengthy bureaucratic processes.
For many Americans, the debate surrounding the FDA reflects a broader national conversation about health, accountability, and trust in public institutions. As chronic disease rates continue to rise and concerns over the food supply grow, many are calling for greater transparency, stronger oversight, and policies that put the well-being of families ahead of corporate interests. Amid these concerns, let’s pray for the FDA and it’s new acting commissioner!
What changes would you like to see in America’s food and healthcare systems? Share your thoughts and prayers below.
(Excerpt from Just the News. Photo Credit: The U.S. Food and Drug Administration)
